The ENROLL Act of 2025 modifies the Affordable Care Act's navigator program, which helps people enroll in health insurance. It requires states and federal exchanges to award grants based on an entity’s capacity to provide services, not whether they cover non-qualified health plans, and ensures at least one annual grant goes to community-focused nonprofits. The bill expands navigators’ duties to include explaining Medicaid and children’s health insurance programs (CHIP) in clear language, mandates in-person assistance options, and allocates $100 million annually from insurer user fees for federal exchanges starting in 2026. These changes directly affect navigators, health insurance exchanges, and consumers seeking coverage under the Affordable Care Act.
The ADAPT Act (S 2356) expands Medicare coverage to include services provided by advanced psychology trainees - such as doctoral interns and postdoctoral residents in APA-accredited programs - under the general supervision of a licensed clinical psychologist (without requiring the supervisor's physical presence during services). It mandates the creation of a new billing code (GC modifier) for these services and directs the Department of Health and Human Services to issue guidance to states on covering these services under Medicaid and CHIP. This bill directly affects trainees, Medicare beneficiaries, and state Medicaid programs by streamlining access to mental health care through standardized billing and coverage mechanisms.
S 3302, the Mikaela Naylon Give Kids a Chance Act of 2025, requires drug manufacturers developing cancer treatments to conduct pediatric-focused research for certain drugs targeting pediatric cancer mechanisms. It amends FDA drug approval processes to mandate molecularly targeted pediatric cancer investigations for drugs with new active ingredients or specific approved combinations, ensuring studies address dosing, safety, and efficacy for children. The bill also extends priority review vouchers (which expedite FDA reviews) for rare pediatric disease treatments until 2030 and mandates GAO studies to evaluate how effectively these incentives spur new pediatric cancer drug development. These changes apply to new drug applications submitted three years after the law's enactment, with reports due to Congress at 6, 8, and 10 years.
This bill removes an age limit that previously restricted continuous Medicaid and CHIP coverage to children under 19. It changes the rules to apply 12-month continuous enrollment protections to all enrollees, regardless of age, by replacing "child" and age-specific language with "individual" throughout the program rules. The key mechanism is amending federal law to eliminate the requirement that beneficiaries must be under 19 to qualify for uninterrupted coverage. This directly affects all current and future Medicaid and CHIP participants, including adults and older children. The changes take effect in 2026.
The Easy Enrollment in Health Care Act (S 2057) creates a system that allows taxpayers to use their federal tax returns to determine eligibility for health insurance programs and automatically enroll household members in coverage with no out-of-pocket costs (zero net premium) if eligible. The bill establishes a process where taxpayers can consent to sharing tax return information (with privacy protections) with health insurance exchanges to determine eligibility for Medicaid, CHIP, or subsidized marketplace plans, eliminating the need for separate applications. It creates a "single, streamlined application" that minimizes the information needed from taxpayers by leveraging existing tax data for eligibility determinations, with procedures for error correction and privacy safeguards. The program is designed to simplify enrollment in health insurance programs by using tax return information, with implementation required by January 1, 2028.
The Give Kids a Chance Act of 2025 modifies FDA regulations to improve pediatric cancer drug development and extends incentives for rare pediatric disease treatments. It requires drug developers seeking approval for molecularly targeted cancer drugs to include pediatric-focused studies (e.g., dosing, safety) for specific cancer types, with new FDA guidance due within 12 months. The bill also extends the rare pediatric disease priority review voucher program through 2029 and mandates a GAO study to evaluate how effectively these vouchers spur development of treatments for rare pediatric diseases, reporting findings by 2034. This directly affects pharmaceutical companies developing cancer drugs and the FDA’s approval process, aiming to accelerate treatments for children with cancer and rare diseases.
The ENROLL Act of 2025 amends the Affordable Care Act to strengthen the navigator program that helps people enroll in health insurance. It requires state and federal exchanges to award grants to navigators based on their capacity to provide services, not whether they cover non-qualified health plans, and mandates annual grants to community-focused nonprofits. Navigators must now provide information about Medicaid and CHIP programs in plain language and maintain physical presence in their states for in-person assistance. The bill allocates $100 million annually from health insurer user fees to fund federal exchange navigators starting in fiscal year 2026. These changes directly affect navigators, state/federal health insurance exchanges, and consumers seeking coverage.
# Summary of the Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026
This comprehensive appropriations bill allocates funding for the fiscal year 2026 to the Department of Labor, Department of Health and Human Services (HHS), Department of Education, and several related agencies. The bill contains numerous specific funding allocations, restrictions, and procedural requirements.
Key elements include:
1. **Major Funding Areas**:
- HHS receives significant funding for programs including Medicaid, CHIP, Social Security, and public health initiatives
- Education receives substantial funding for student financial assistance, career and technical education, and research
- Related agencies receive funding for programs like the Corporation for National and Community Service and the Social Security Administration
2. **Key Restrictions**:
- Prohibits using funds for abortions except in cases of rape, incest, or to save a woman's life (Section 506-507)
- Bans funding for embryonic research or creation of human embryos for research (Section 508)
- Prohibits funding for advocacy of drug legalization (Section 509)
- Requires transparency in reporting how federal funds are used (Section 505)
- Prohibits using funds for propaganda or political activities (Section 503)
3. **Specific Provisions**:
- Requires detailed reporting to Congress about fund usage (Sections 516-517)
- Mandates notification to Congress before reprogramming funds (Section 514)
- Includes numerous rescission provisions that cancel previously appropriated funds
- Contains specific requirements for managing federal contracts and grants
- Establishes restrictions on using funds for certain types of research or activities
4. **Notable Funding Amounts**:
- $24.6 billion for Student Financial Assistance
- $49.4 billion for the Supplemental Security Income Program
- $14.7 billion for Social Security Administration administrative expenses
- $3.2 billion for Higher Education programs
- $2.1 billion for Career, Technical, and Adult Education
The bill represents a comprehensive funding package with specific constraints on how funds may be used, reflecting ongoing policy debates about government spending priorities in health, education, and social services.
S 3421 requires medical device manufacturers and importers to use a standardized electronic system for recall notifications. This system must include specific mandatory information like device identifiers, risk details, and patient safety instructions, and must be shared with health professionals and patients for high-risk recalls (e.g., implanted, life-sustaining, or pediatric devices). The bill mandates that manufacturers submit these notifications electronically to the FDA within 180 days of the system's launch, with the FDA reviewing them within 2 business days. It also creates a public, searchable database of all recall information. The law directly affects device manufacturers, healthcare facilities, and patients receiving affected devices.
S 2131, the Dads Matter Act of 2025, requires the Health and Human Services Secretary to launch a public awareness campaign within two years and issue state guidance within one year to improve father involvement in prenatal and postpartum care. The campaign will promote father engagement through public messaging, while the guidance will direct states to train healthcare providers (like OB-GYNs and hospitals) on supporting fathers’ roles during pregnancy and early childcare. Key provisions focus on increasing prenatal care attendance, reducing maternal health risks, improving breastfeeding success, and promoting father-infant bonding. This policy directly affects healthcare systems nationwide by changing provider practices to better include fathers in maternal and infant health support.
